CLINICAL TRIALS PROFILE FOR IVABRADINE
✉ Email this page to a colleague
All Clinical Trials for ivabradine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00143507 ↗ | The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction | Completed | Institut de Recherches Internationales Servier | Phase 3 | 2004-12-01 | The aim of this study is to test whether ivabradine is able to reduce cardiovascular events when given to patients with coronary artery disease and impaired heart function. |
| NCT00202566 ↗ | Efficacy and Safety of Ivabradine on Top of Atenolol in Stable Angina Pectoris | Completed | Institut de Recherches Internationales Servier | Phase 3 | 2005-06-01 | To test whether ivabradine when given in combination with atenolol is able to improve the exercise tolerance of patients with stable angina pectoris |
| NCT00202579 ↗ | Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure | Completed | Institut de Recherches Internationales Servier | Phase 2 | 2004-09-01 | To evaluate the effects on heart function of ivabradine administered to patients with severe chronic heart failure |
| NCT00757055 ↗ | If Channel Blockade With Ivabradine in Patients With Diastolic Heart Failure | Withdrawn | St Vincent's University Hospital, Ireland | Phase 2 | 2012-12-01 | The purpose of this study is to investigate whether the medicine ivabradine, a novel drug which slows the heart rate has a favourable effect on patients with diastolic heart failure. Ivabradine is a specific heart rate-lowering agent. It has a licence for treating patients with angina who are intolerant of agents such as beta blockers or whose angina is not adequately controlled. It has been shown to prolong exercise tolerance in these patients and to reduce the frequency of chest pain. Its mechanism of action is felt to be purely due to reducing heart rate, by as much as 10 beats per minute at rest, as well as by reducing the heart rate response to exercise. Patients with diastolic heart failure often complain of breathlessness on exertion which relates to the stiffness or lack of compliance of their heart i.e. the heart fails to relax rapidly enough to allow it to fill with blood between each heart beat. This may result in high pressure in the heart chamber which backs up in to the lungs and may be experienced as breathlessness. There is little evidence that any specific therapy benefits patients with this type of heart failure besides treating coexisting problems such as high blood pressure or angina. By slowing the heart rate down with ivabradine, the heart would have a longer time to fill during exercise which would make it more effective. This slowing of the heart rate may therefore relieve the breathlessness experienced on activity such as walking to the shops or up a flight of stairs etc. |
| NCT00815100 ↗ | Effects of the Ivabradine on Reduction of Inflammatory Markers in Patients With Acute Coronary Syndrome | Completed | Hospital Universitario de Canarias | Phase 4 | 2009-04-01 | The purpose of this study is to investigate whether a pure heart rate-lowering agent (Ivabradine) reduces vascular inflammatory stress in patients with acute coronary syndromes |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ivabradine
Condition Name
Clinical Trial Locations for ivabradine
Trials by Country
Clinical Trial Progress for ivabradine
Clinical Trial Phase
Clinical Trial Sponsors for ivabradine
Sponsor Name
